News | April 07, 2008

Stubborn High Blood Pressure May Need Special Care

April 8, 2008 - People who are taking three or more drugs and still have high blood pressure have a condition known as resistant hypertension that may require special treatment, the American Heart Association said on Monday.

The guidelines are intended to help doctors and patients identify and control resistant hypertension, which affects as many as 30 percent of people with high blood pressure.

"It may be the fastest-growing component of hypertension in general - those patients needing three or more medicines," David Calhoun, M.D., of the University of Alabama at Birmingham and chair of the association's guideline writing committee said in a telephone interview.

Given that older age and obesity are two of the strongest risk factors associated with this kind of hypertension, the condition will likely become increasingly common as the U.S. population ages and grows heavier, Dr. Calhoun said.

Under the new guidelines, published online in the journal Hypertension, resistant hypertension also includes people who must take four or more drugs before they can get their blood pressure under control.

High blood pressure affects about 73 million people in the United States and an estimated 1 billion people globally. Poorly controlled hypertension increases the risk of heart attacks, stroke, kidney failure and heart failure.

"These patients with resistant hypertension are probably at even increased risk because of their long-standing, poorly controlled hypertension," Dr. Calhoun said.

Dr. Calhoun said the guidelines are the first to specifically address the treatment of resistant hypertension, which he said may be brought on by underlying conditions that need to be managed.
"Obesity, a high-salt diet, and sleep apnea are common contributing causes," he said. Resistant hypertension may also result from an excess of a hormone produced in the adrenal gland known as aldosterone, which can promote fluid retention.

Kidney disease and diabetes are also important contributors, Dr. Calhoun said.

The new guidelines stress that treatment should be tailored to individual patients and their underlying conditions.

If blood pressure cannot be controlled after working with a general doctor for six months, Dr. Calhoun said people should referred to a specialist.

(Editing by Maggie Fox and Eric Walsh)


For more information:

Related Content

Resolute Onyx Stent With Improved Radiographic Visibility Found to Be Safe and Effective
News | Stents Drug Eluting | October 01, 2018
October 1, 2018 — Recent results from the BIONYX randomized clinical study showed the novel, thin-strutted, polymer-c
Boston Scientific Receives FDA Approval for Eluvia Drug-Eluting Vascular Stent
Technology | Stents Drug Eluting | October 01, 2018
Boston Scientific announced that the U.S. Food and Drug Administration (FDA) has approved its Premarket Approval (PMA)...
Eluvia Drug-Eluting Stent Demonstrates Superior Patency in IMPERIAL Trial
News | Stents Drug Eluting | September 26, 2018
Positive 12-month data from the late-breaking IMPERIAL trial was presented at the 2018 Transcatheter Cardiovascular...
Titanium-Nitride-Oxide Stent Superior to Bioabsorbable DES in Acute Coronary Syndrome Patients

Image courtesy of Hexacath

News | Stents Drug Eluting | May 31, 2018
Late-breaking trial results presented at the EuroPCR Congress, May 21-24 in Paris, France, found the Optimax titanium-...
Orsiro DES Shows Lowest Two-Year Target Lesion Failure in BIO-RESORT Trial
News | Stents Drug Eluting | May 31, 2018
Two-year outcome data from the BIO-RESORT randomized controlled trial were presented in a late-breaking clinical trials...
OCT Reveals Excellent Healing Profile for Complex CAD Patients With Resolute Onyx DES
News | Stents Drug Eluting | May 29, 2018
Investigators recently unveiled clinical data from the independently run Onyx 1-Month OCT Study showing strong early...
Abbott's Xience Sierra Stent Receives FDA Approval
Technology | Stents Drug Eluting | May 25, 2018
Abbott announced it received approval from the U.S. Food and Drug Administration (FDA) for Xience Sierra, the newest...
Medtronic Launches 2 mm Onyx DES
Technology | Stents Drug Eluting | February 26, 2018
February 26, 2018 – Designed specifically for small vessels, Medtronic plc announced U.S.
Detroit Medical Center Heart Hospital Uses Michigan's First EluNIR Drug-Eluting Stent
News | Stents Drug Eluting | February 19, 2018
February 19, 2018 — The Detroit Medical Center’s (DMC) interventional cardiology team at Heart Hospital recently beca
Biotronik Symposium Highlights Differing Roles of Drug-Eluting Stents and Magnesium Scaffolds in Clinical Practice
News | Stents Drug Eluting | January 25, 2018
January 25, 2018 – Data presented at the Biotronik-sponsored...
Overlay Init